Restriction of use of dronedarone (Multaq®)

The Health Sciences Authority (HSA) would like to alert healthcare professionals on its assessment of the benefit-risk profile of dronedarone (Multaq®, Sanofi-aventis) following the recent findings from a prematurely terminated clinical study, PALLAS (Permanent Atrial FibriLLAtion Outcome Study Using Dronedarone on Top of Standard Therapy). The use of dronedarone will be restricted to patients with history of non-permanent atrial fibrillation in sinus rhythm for the maintenance of sinus rhythm after alternative treatment options have been considered.

 
 
Healthcare professional, Therapeutic Products
Published:

Dear Healthcare Professional Letters

24 Feb 2021

Only abstracts of the Dear Healthcare Professional Letters (DHCPL) are provided on this website. Details of the letters can be found on the MOH Alert System, which is accessible via the Health Professionals Portal (HPP), a one-stop portal for all healthcare professionals in Singapore. Dentists, medical doctors and pharmacists may access HPP at https://www.hpp.moh.gov.sg and follow the procedures below to access the MOH Alert system.

Step 1: Select your profession under 'For Healthcare Professionals’.

Step 2: Click on 'Restricted Content' and log in via SingPass.

Step 3: Click on the MOH Alert icon under ‘Applications’.

Step 4: Click on the Drug Alert tab to view the DHCPLs.